middle.news
How Telix’s 56% Revenue Surge Fuels Its Radiopharmaceutical Revolution
9:04am on Friday 20th of February, 2026 AEDT
•
Healthcare
Read Story
How Telix’s 56% Revenue Surge Fuels Its Radiopharmaceutical Revolution
9:04am on Friday 20th of February, 2026 AEDT
Key Points
56% revenue growth to US$803.8 million in 2025
Net loss of US$7.1 million due to increased R&D and manufacturing scale-up
Phase 3 trial underway for prostate cancer therapy TLX591-Tx
Acquisition of RLS Radiopharmacies expands U.S. manufacturing and distribution
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE